Alio

The Alio system utilizes a wearable SmartPatch sensor to collect and wirelessly transmit physiological data, including hemoglobin, hematocrit, skin temperature, heart rate, auscultation sounds, and a photoplethysmography-derived qualitative potassium indicator, to a cloud-based portal for healthcare provider review. It is particularly aimed at monitoring general care patients and those with end-stage kidney disease, employing an AI/ML algorithm for deriving certain parameters when the patch is placed on an arteriovenous access site.

The Alio system is a wireless remote monitoring tool designed for healthcare providers to collect various physiological data from patients in both clinical and non-clinical environments. It comprises several components: the Alio SmartPatch, a flexible, silicone-encased wearable sensor; the Alio Hub, which communicates with the SmartPatch via Bluetooth and transmits data to the Alio Cloud via cellular connection; the Alio Cloud, a secure server for data storage and processing; and the Alio Portal, a web-based interface for healthcare providers to visualize and interact with the patient data. The SmartPatch is designed to be worn for up to seven days, typically between cannulation sites of an arteriovenous access in specific patient populations. The system measures hemoglobin (Hgb) and hematocrit (Hct), skin temperature, heart rate, and records auscultation sound data. Additionally, it provides a qualitative indicator of abnormal potassium levels, derived from the relative variability of photoplethysmography (PPG) waveforms and medically accepted thresholds. The Alio system is intended for use on general care patients aged 18 years or older. For ESKD patients, the SmartPatch is specifically indicated for placement on an arm-based arteriovenous access site to provide measurements of heart rate, skin temperature, Hgb, Hct, and the qualitative potassium risk assessment. It serves as a secondary, adjunct monitor and is not intended to replace standard patient monitoring or be the sole basis for therapeutic decisions, including those related to dyskalemia.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the detailed methodology and validation for the qualitative potassium indicator derived from photoplethysmography waveform variability, especially concerning medically accepted threshold values?; How does the AI/ML algorithm differentiate and accurately measure hemoglobin and hematocrit in patients with varying degrees of arteriovenous access site characteristics or perfusion levels?; What are the specific performance metrics (e.g., sensitivity, specificity, accuracy) of the auscultation sound data recording and transmission for detecting relevant clinical sounds?; Beyond general HIPAA compliance, what specific data security measures are in place for the transmission and storage of physiological data from the SmartPatch through the Hub to the Cloud and Portal, particularly concerning AI/ML model integrity?; What was the range of skin temperatures observed in the clinical study, and how does the device account for potential variations in ambient temperature affecting skin temperature readings?